Loading…
Loading…
Structured register of government actions in the geoeconomic space — export controls, tariffs, sanctions, FDI screening, subsidies, industrial-policy laws — cross-referenced into the country, minerals, and ETF surface. Charter: docs/IPTM_CHARTER.md.
Severity 1-5 is the qualitative impact rating (1=minor, 5=structural). The bilateral-trade-grounded quant scorer is the next IPTM milestone. RBI (Register Breadth Index) is a complementary structural-breadth indicator from scripts/py/iptm/breadth.py; divergence between RBI and severity is itself informative (high-sev / low-RBI = strategic chokepoint; low-sev / high-RBI = broad but shallow). Every action has at least one primary source URL. Verify-or-don't-file. See also themes, timeline, graph, sankey, map, country exposure, sector exposure, material exposure (+ graph), weekly briefs, portfolio scan, escalation monitor, trans-shipment hubs. Internal triage tools (RSS-poller candidate feed, source-feed health) live under /admin/candidates + /admin/sources. Subscribe via Atom feed (accepts ?country=CN, ?material=lithium, ?issuer=BIS, ?type=export_control, ?etf=SOXX, ?company=NVDA, ?minSeverity=4, ?year=2026, ?q=…) or pull /api/iptm/actions.
The European Commission approved a €400 million German measure in favour of Sanofi-Aventis Deutschland GmbH under EU State aid rules, structured as public service compensation for a service of general economic interest (SGEI) to strengthen the resilience of German/EU insulin supply against production and shortage risk. As its public service obligation, Sanofi must build a new insulin factory at its Industriepark Frankfurt-Höchst site by 31 December 2032 and maintain annual production of at least 1.1 tonnes of insulins there through 31 December 2042.
Brazil's federal innovation-financing agency FINEP (Financiadora de Estudos e Projetos), under the MCTI/FNDCT umbrella, published a BRL 300 million (~USD 51.7 million) public call — "Finep Mais Inovação Brasil – Rodada 2 – Saúde" — offering non-repayable economic-subsidy grants for private-sector R&D of innovative products or processes for Brazil's health-industrial complex (pharmaceuticals, health-sector chemical inputs). A minimum BRL 90 million is reserved for projects based in the North, Northeast or Center-West regions. Proposal submission opened 2026-02-06 and runs through 2026-09-18.
The Commonwealth of Pennsylvania, via Governor Josh Shapiro's office and the Department of Community & Economic Development, assembled a $100 million public incentive package — up to $50 million via the PA Edge Tax Credit Program, a $25 million PA SITES (Strategic Investments to Enhance Sites) grant, a $25 million Pennsylvania First grant, and up to $5 million via the Redevelopment Assistance Capital Program (RACP) for workforce development — to secure a $3.5 billion private investment from Eli Lilly and Company, the company's first manufacturing facility in Pennsylvania. The 925,000-square-foot facility will be built at the Fogelsville Corporate Center in Upper Macungie Township, Lehigh County, to produce next-generation weight-loss medicines, creating at least 850 new jobs over five years. It is the largest life-sciences investment in Pennsylvania history.
The European Investment Bank signed a EUR 400 million, seven-year loan agreement with Swedish hygiene and health group Essity on 29 January 2026 (EIB project ref. 20210374, "Essity Health and Hygiene Products RDI") to finance research, development and innovation expenditure at Essity's R&D centres in Sweden, Germany and France over 2025-2028. The financing targets product and process development across Personal Care, Professional Hygiene and medical wound care, with emphasis on replacing fossil-based plastics with bio-based materials, cutting greenhouse-gas emissions and expanding digital manufacturing solutions; roughly 30% of the RDI spend is earmarked for feminine-care and incontinence-product research. Global Trade Alert separately logs the transaction as a "red"-flagged state-linked lending intervention (state act 96020 / intervention 151945).
On 26 January 2026 Beijing's Dongcheng District (via the Zhongguancun Science Park Dongcheng Zone Management Committee and the district Science and Technology Commission) issued Notice 东城园文〔2026〕2号, "Several Measures of Beijing Dongcheng District on Promoting High-Quality Development of the Pharmaceutical and Health Industry," effective 25 February 2026. The 14-article package spans seven chapters covering traditional-Chinese-medicine industry development, product-innovation value realisation, digital medical services, innovative-medicine support, and talent services, with cash grants of up to RMB 20 million per project and up to RMB 10 million per year for a single market entity in the medical-device segment. A draft version was open for public comment from 18 December 2025 to 17 January 2026 before formal issuance.
The British Business Bank, the UK government's state-owned economic development bank, announced a GBP 50 million cornerstone commitment to Epidarex Capital's new life sciences fund on 20 January 2026. The fund, Epidarex Capital IV, LP, went on to announce a first close of USD 145 million on 27 January 2026, with the Bank joined by the Strathclyde Pension Fund, the Scottish National Investment Bank, and other family-office and corporate investors. This is the Bank's second cornerstone commitment to an Epidarex fund, following a GBP 50 million stake in Epidarex Capital III UK, LP in 2020.
China's Ministry of Finance, NDRC, Ministry of Industry and Information Technology, People's Bank of China and National Financial Regulatory Administration jointly issued Cai Jin [2026] No. 4 on 2026-01-19, establishing a central-fiscal loan interest-subsidy scheme for micro, small and medium-sized enterprises (MSMEs) operating in 14 designated industrial-chain and emerging-industry sectors. Eligible loans originated from 2026-01-01 receive a 1.5-percentage-point annual interest subsidy for up to two years, capped at RMB 50 million in principal per enterprise (maximum subsidy RMB 1.5 million per enterprise). The policy is tentatively set to run one year with a possible extension.